Sandoz Group AG (SDZNY)
OTCMKTS · Delayed Price · Currency is USD
73.81
-1.41 (-1.87%)
At close: Jan 13, 2026
Sandoz Group AG Revenue
Sandoz Group AG had revenue of $5.27B in the half year ending June 30, 2025, with 6.80% growth. This brings the company's revenue in the last twelve months to $10.59B, up 4.71% year-over-year. In the year 2024, Sandoz Group AG had annual revenue of $10.38B with 4.06% growth.
Revenue (ttm)
10.59B
Revenue Growth
+4.71%
P/S Ratio
3.01
Revenue / Employee
529.35K
Employees
22,049
Market Cap
31.84B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.38B | 405.00M | 4.06% |
| Dec 31, 2023 | 9.98B | 673.00M | 7.23% |
| Dec 31, 2022 | 9.31B | -372.00M | -3.84% |
| Dec 31, 2021 | 9.68B | 20.00M | 0.21% |
| Dec 31, 2020 | 9.66B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Vaxart | 148.20M |
| Elite Pharmaceuticals | 122.89M |
| Zomedica | 29.45M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
Sandoz Group AG News
- 25 days ago - SDZNY vs. STVN: Which Stock Is the Better Value Option? - Nasdaq
- 5 weeks ago - Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Dr. Reddy's - Nasdaq
- 5 weeks ago - Sandoz Completes Acquisition Of Just-Evotec Biologics - Nasdaq
- 5 weeks ago - Evotec Closes Sale of Just - Evotec Biologics' Toulouse Site to Sandoz - Accesswire
- 5 weeks ago - Sandoz Group AG Sponsored ADR (SDZNY) Upgraded to Buy: Here's Why - Nasdaq
- 5 weeks ago - SDZNY vs. STVN: Which Stock Should Value Investors Buy Now? - Nasdaq
- 6 weeks ago - Sandoz Launches Wyost And Jubbonti In Europe - Nasdaq
- 2 months ago - Sandoz Announces Launch Of TYRUKO In The US - Nasdaq